IBT B — Infant Bacterial Therapeutics AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK649.32m
- SEK505.31m
Annual cashflow statement for Infant Bacterial Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -44.6 | -65.8 | -135 | -145 | -69 |
| Depreciation | |||||
| Non-Cash Items | -19.3 | -33.3 | 2.07 | -5.45 | 7.28 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 7.4 | 12.5 | 30.5 | 36.8 | -11.4 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -55.6 | -85.8 | -101 | -113 | -72.3 |
| Financing Cash Flow Items | — | -0.02 | -5.03 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.091 | 1.88 | 96.5 | 2.01 | 0 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -36.7 | -50.9 | -6.78 | -106 | -65.3 |